Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $26.49, for a total value of $5,298,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,654,597 shares in the company, valued at approximately $43,830,274.53. This represents a 10.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, January 12th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $21.92, for a total transaction of $4,384,000.00.
• On Wednesday, December 24th, Eric Venker sold 75,000 shares of Roivant Sciences stock. The stock was sold at an average price of $22.53, for a total transaction of $1,689,750.00.
• On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.45, for a total transaction of $4,490,000.00.
• On Tuesday, December 9th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.85, for a total value of $4,170,000.00.

Roivant Sciences Trading Up 0.1%

NASDAQ:ROIV opened at $27.52 on Friday. The stock has a 50-day moving average price of $23.22 and a 200 day moving average price of $18.75. The stock has a market capitalization of $19.70 billion, a P/E ratio of -23.52 and a beta of 1.22. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $27.94.

Institutional Investors Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ROIV. Goldman Sachs Group Inc. lifted its position in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after buying an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Roivant Sciences by 1.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock valued at $24,678,000 after acquiring an additional 34,341 shares during the period. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Roivant Sciences by 28.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 43,612 shares of the company’s stock worth $492,000 after acquiring an additional 9,548 shares during the last quarter. CWM LLC boosted its stake in shares of Roivant Sciences by 44.6% during the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after purchasing an additional 920 shares during the period. Finally, TD Asset Management Inc bought a new position in Roivant Sciences during the 2nd quarter valued at about $1,830,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Leerink Partners raised their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Weiss Ratings lowered Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, February 9th. Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. The Goldman Sachs Group increased their price target on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, HC Wainwright lifted their price objective on Roivant Sciences from $26.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.69.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.